Vega Stem Cell (vegastemcell.com) proudly participated in a significant strategic meeting held at the Thailand Institute of Scientific and Technological Research (TISTR) on March 18, 2025. The event featured Dr. Burin Nuchniyom, a leading figure in regenerative medicine and oncology, who engaged in high-level discussions alongside experts from Agem Biotech—a spin-off from the National University of Singapore (NUS)—and senior officials from TISTR.
This hybrid meeting, combining both in-person and virtual attendance via Zoom, was attended by notable figures including Dr. Burin Nuchniyom, Deputy Director of Piyavate Hospital and member of the ATMP board; Dr. Hongthai Tan, an advisor to TISTR; and Associate Professor Heng-Phon Too along with a research team from NUS.
The primary objective of the session was to foster international collaboration in stem cell therapies and biomedical innovation through joint development initiatives. Special emphasis was placed on strategies for translating research into clinically approved stem cell treatments, with a focus on therapies targeting solid tumors.
Strengthening Thailand–Singapore Collaboration in Stem Cell Therapy
The meeting highlighted the critical role of technology transfer and scientific exchange between Thailand and Singapore in advancing regenerative medicine. The NUS research team, led by Assoc. Prof. Heng-Phon Too, presented advancements in next-generation stem cell technologies aimed at combating treatment-resistant tumors through targeted cell-based methods.
Dr. Burin Nuchniyom, recently appointed Director of the new cancer center at Piyavate Hospital—an institution backed by over USD 20 million in investment—offered insights into the readiness of clinical infrastructure and the necessary pathways to integrate these technologies into Thailand’s healthcare system. In his role on TISTR’s ATMP board, Dr. Burin plays a pivotal part in linking research innovations with clinical policy and safety standards.
TISTR’s Role in Advancing Medical Biotechnology in Thailand
This event was part of TISTR’s ongoing dedication to enhancing Thailand’s medical biotechnology capabilities and facilitating the commercialization of stem cell products. TISTR officials explained that the meeting aimed to establish a foundation for jointly developing therapeutic innovations that address both national healthcare needs and comply with international standards.
Key topics discussed included:
- Collaborative development of stem cell-based therapies for cancer and immune-related diseases
- Standardization of production processes and quality control for stem cell treatments
- Positioning Thailand as a leading destination for regenerative medical tourism
- Delivering high-quality and affordable stem cell therapies to the market
The meeting concluded with a mutual commitment to pursue further collaborative efforts in research, pilot-scale manufacturing, and regulatory alignment to accelerate clinical adoption.
Importantly, discussions also focused on integrating stem cell innovations from the National University of Singapore into Thailand’s biotechnology ecosystem. Contributions from the ethics committee ensured that all research and development initiatives remain patient-focused and adhere to international biomedical ethical standards.
Vega Stem Cell (vegastemcell.com): Championing Global Adoption of Stem Cell Treatments
As the facilitator of this important engagement, Vega Stem Cell (vegastemcell.com) reaffirmed its commitment to advancing the global adoption of stem cell therapies. With a strong foundation within Thailand’s healthcare system and established connections to international research networks, Vega plays a pivotal role in translating innovative cell therapies into clinical practice.
The company remains focused on:
- Raising awareness and improving access to stem cell-based treatments
- Investing in GMP-compliant production of therapeutic cells
- Fostering cross-border research collaborations and training programs
- Developing ethical, safe, and effective clinical treatment protocols
Vega Stem Cell’s mission closely aligns with Thailand’s wider goal of becoming a regional hub for stem cell innovation, supported by key government bodies such as TISTR and leading hospital partners including Piyavate.
The Global Outlook for Stem Cell Therapy
Globally, stem cell therapies are increasingly recognized as promising alternatives for treating complex diseases such as cancer, autoimmune disorders, neurodegenerative conditions, and orthopedic injuries. As scientific knowledge progresses and clinical successes accumulate, healthcare systems worldwide are embracing the transformative potential of regenerative medicine.
Thailand, benefiting from its strategic location, strong scientific expertise, and expanding international collaborations, is well-positioned to become a leading center for advanced stem cell treatments.
Through collaborations with institutions like the National University of Singapore (NUS) and leaders such as Dr. Burin Nuchniyom, Vega Stem Cell (vegastemcell.com) is playing a crucial role in broadening therapeutic options in Thailand while actively contributing to the global advancement of personalized and regenerative healthcare.
Conclusion
The event on March 18 marks a crucial milestone in Vega Stem Cell’s ongoing commitment to driving world-class innovation within the stem cell industry. By cultivating strong partnerships among key players in biotechnology, clinical practice, and research across the region, Vega is helping to realize the full potential of stem cell therapies for patients globally.
Vega expresses its sincere appreciation to TISTR, NUS, and Dr. Burin Nuchniyom for their shared vision and dedication to advancing the field of cellular medicine. With continued cooperation and support, the future of regenerative medicine in Asia is more promising than ever.
Contact Information
Vega Medical Services
3/6, The Primary 101, Soi Lad Phrao 101,
Lad Phrao Road, Khlong Chan, Bang Kapi District,
Bangkok 10240, Thailand
Email: vegastemcell@gmail.com
Tel & WhatsApp: +66 (0) 86 691 6915